Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment : A pilot study. / Andersen, Martin; Boesen, Mikael; Ellegaard, Karen; Söderström, Kalle; Søe, Niels H; Spee, Pieter; Mørch, Ulrik G W; Torp-Pedersen, Søren; Bartels, Else M; Danneskiold-Samsøe, Bente; Karlsson, Lars; Bliddal, Henning.

I: PLoS ONE, Bind 13, Nr. 5, e0197001, 2018.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, M, Boesen, M, Ellegaard, K, Söderström, K, Søe, NH, Spee, P, Mørch, UGW, Torp-Pedersen, S, Bartels, EM, Danneskiold-Samsøe, B, Karlsson, L & Bliddal, H 2018, 'Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study', PLoS ONE, bind 13, nr. 5, e0197001. https://doi.org/10.1371/journal.pone.0197001

APA

Andersen, M., Boesen, M., Ellegaard, K., Söderström, K., Søe, N. H., Spee, P., ... Bliddal, H. (2018). Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study. PLoS ONE, 13(5), [e0197001]. https://doi.org/10.1371/journal.pone.0197001

Vancouver

Andersen M, Boesen M, Ellegaard K, Söderström K, Søe NH, Spee P o.a. Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study. PLoS ONE. 2018;13(5). e0197001. https://doi.org/10.1371/journal.pone.0197001

Author

Andersen, Martin ; Boesen, Mikael ; Ellegaard, Karen ; Söderström, Kalle ; Søe, Niels H ; Spee, Pieter ; Mørch, Ulrik G W ; Torp-Pedersen, Søren ; Bartels, Else M ; Danneskiold-Samsøe, Bente ; Karlsson, Lars ; Bliddal, Henning. / Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment : A pilot study. I: PLoS ONE. 2018 ; Bind 13, Nr. 5.

Bibtex

@article{dad2a7661c3e474597718d4412b0afc9,
title = "Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study",
abstract = "INTRODUCTION: The need for biomarkers which can predict disease course and treatment response in rheumatoid arthritis (RA) is evident. We explored whether clinical and imaging responses to biologic disease modifying anti-rheumatic drug treatment (bDMARD) were associated with the individual's mediator production in explants obtained at baseline.METHODS: RA Patients were evaluated by disease activity score 28 joint C-reactive protein (DAS 28-)), colour Doppler ultrasound (CDUS) and 3 Tesla RA magnetic resonance imaging scores (RAMRIS). Explants were established from synovectomies from a needle arthroscopic procedure prior to initiation of bDMARD. Explants were incubated with the bDMARD in question, and the productions of interleukin-6 (IL-6), monocyte chemo-attractive protein-1 (MCP-1) and macrophage inflammatory protein-1-beta (MIP-1b) were measured by multiplex immunoassays. The changes in clinical and imaging variables following a minimum of 3 months bDMARD treatment were compared to the baseline explant results. Mixed models and Spearman's rank correlations were performed. P-values below 0.05 were considered statistically significant.RESULTS: 16 patients were included. IL-6 production in bDMARD-treated explants was significantly higher among clinical non-responders compared to responders (P = 0.04), and a lack of suppression of IL-6 by the bDMARDS correlated to a high DAS-28 (ρ = 0.57, P = 0.03), CDUS (ρ = 0.53, P = 0.04) and bone marrow oedema (ρ = 0.56, P = 0.03) at follow-up. No clinical association was found with explant MCP-1 production. MIP-1b could not be assessed due to a large number of samples below the detection limit.CONCLUSIONS: Synovial explants appear to deliver a disease-relevant output testing which when carried out in advance of bDMARD treatment can potentially pave the road for a more patient tailored treatment approach with better treatment effects.",
keywords = "Adult, Aged, Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/diagnostic imaging, Case-Control Studies, Chemokine CCL2/metabolism, Female, Humans, Image Processing, Computer-Assisted/methods, In Vitro Techniques, Interleukin-6/analysis, Male, Middle Aged, Pilot Projects, Prognosis, Synovial Membrane/diagnostic imaging, Tissue Culture Techniques, Ultrasonography, Doppler, Color/methods",
author = "Martin Andersen and Mikael Boesen and Karen Ellegaard and Kalle S{\"o}derstr{\"o}m and S{\o}e, {Niels H} and Pieter Spee and M{\o}rch, {Ulrik G W} and S{\o}ren Torp-Pedersen and Bartels, {Else M} and Bente Danneskiold-Sams{\o}e and Lars Karlsson and Henning Bliddal",
year = "2018",
doi = "10.1371/journal.pone.0197001",
language = "English",
volume = "13",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

RIS

TY - JOUR

T1 - Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment

T2 - A pilot study

AU - Andersen, Martin

AU - Boesen, Mikael

AU - Ellegaard, Karen

AU - Söderström, Kalle

AU - Søe, Niels H

AU - Spee, Pieter

AU - Mørch, Ulrik G W

AU - Torp-Pedersen, Søren

AU - Bartels, Else M

AU - Danneskiold-Samsøe, Bente

AU - Karlsson, Lars

AU - Bliddal, Henning

PY - 2018

Y1 - 2018

N2 - INTRODUCTION: The need for biomarkers which can predict disease course and treatment response in rheumatoid arthritis (RA) is evident. We explored whether clinical and imaging responses to biologic disease modifying anti-rheumatic drug treatment (bDMARD) were associated with the individual's mediator production in explants obtained at baseline.METHODS: RA Patients were evaluated by disease activity score 28 joint C-reactive protein (DAS 28-)), colour Doppler ultrasound (CDUS) and 3 Tesla RA magnetic resonance imaging scores (RAMRIS). Explants were established from synovectomies from a needle arthroscopic procedure prior to initiation of bDMARD. Explants were incubated with the bDMARD in question, and the productions of interleukin-6 (IL-6), monocyte chemo-attractive protein-1 (MCP-1) and macrophage inflammatory protein-1-beta (MIP-1b) were measured by multiplex immunoassays. The changes in clinical and imaging variables following a minimum of 3 months bDMARD treatment were compared to the baseline explant results. Mixed models and Spearman's rank correlations were performed. P-values below 0.05 were considered statistically significant.RESULTS: 16 patients were included. IL-6 production in bDMARD-treated explants was significantly higher among clinical non-responders compared to responders (P = 0.04), and a lack of suppression of IL-6 by the bDMARDS correlated to a high DAS-28 (ρ = 0.57, P = 0.03), CDUS (ρ = 0.53, P = 0.04) and bone marrow oedema (ρ = 0.56, P = 0.03) at follow-up. No clinical association was found with explant MCP-1 production. MIP-1b could not be assessed due to a large number of samples below the detection limit.CONCLUSIONS: Synovial explants appear to deliver a disease-relevant output testing which when carried out in advance of bDMARD treatment can potentially pave the road for a more patient tailored treatment approach with better treatment effects.

AB - INTRODUCTION: The need for biomarkers which can predict disease course and treatment response in rheumatoid arthritis (RA) is evident. We explored whether clinical and imaging responses to biologic disease modifying anti-rheumatic drug treatment (bDMARD) were associated with the individual's mediator production in explants obtained at baseline.METHODS: RA Patients were evaluated by disease activity score 28 joint C-reactive protein (DAS 28-)), colour Doppler ultrasound (CDUS) and 3 Tesla RA magnetic resonance imaging scores (RAMRIS). Explants were established from synovectomies from a needle arthroscopic procedure prior to initiation of bDMARD. Explants were incubated with the bDMARD in question, and the productions of interleukin-6 (IL-6), monocyte chemo-attractive protein-1 (MCP-1) and macrophage inflammatory protein-1-beta (MIP-1b) were measured by multiplex immunoassays. The changes in clinical and imaging variables following a minimum of 3 months bDMARD treatment were compared to the baseline explant results. Mixed models and Spearman's rank correlations were performed. P-values below 0.05 were considered statistically significant.RESULTS: 16 patients were included. IL-6 production in bDMARD-treated explants was significantly higher among clinical non-responders compared to responders (P = 0.04), and a lack of suppression of IL-6 by the bDMARDS correlated to a high DAS-28 (ρ = 0.57, P = 0.03), CDUS (ρ = 0.53, P = 0.04) and bone marrow oedema (ρ = 0.56, P = 0.03) at follow-up. No clinical association was found with explant MCP-1 production. MIP-1b could not be assessed due to a large number of samples below the detection limit.CONCLUSIONS: Synovial explants appear to deliver a disease-relevant output testing which when carried out in advance of bDMARD treatment can potentially pave the road for a more patient tailored treatment approach with better treatment effects.

KW - Adult

KW - Aged

KW - Antirheumatic Agents/therapeutic use

KW - Arthritis, Rheumatoid/diagnostic imaging

KW - Case-Control Studies

KW - Chemokine CCL2/metabolism

KW - Female

KW - Humans

KW - Image Processing, Computer-Assisted/methods

KW - In Vitro Techniques

KW - Interleukin-6/analysis

KW - Male

KW - Middle Aged

KW - Pilot Projects

KW - Prognosis

KW - Synovial Membrane/diagnostic imaging

KW - Tissue Culture Techniques

KW - Ultrasonography, Doppler, Color/methods

U2 - 10.1371/journal.pone.0197001

DO - 10.1371/journal.pone.0197001

M3 - Journal article

C2 - 29787569

VL - 13

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 5

M1 - e0197001

ER -

ID: 213037875